amfAR Institute for HIV Cure Research: An Interview with Dr. Paul...
Hide & Seek
Paul Volberding, MD, helps create synergy at the amfAR Institute for Cure Research
by Jeannie Wraight
The amfAR Institute for HIV Cure Research was...
HTVN 702: Vaccine Candidate
Step Forward
Vaccine candidates like HTVN 702 are needed to build momentum
by Jeannie Wraight
If current HIV diagnoses rates persist, about 1 in 2 black men...
Countdown to a Cure
by Jeannie Wraight
As part of the Countdown to a Cure Initiative, amfAR (The Foundation for AIDS Research) will direct $20 million, of a $100...
Talking “Cure”
Nobel Prize Laureate and world renowned HIV researcher Françoise Barré-Sinoussi recently made the statement that she does not believe an HIV cure is possible....
PaxVax’s Vaccine Platform & Other Research Build Momentum
Gaining Momentum
HIV vaccine candidates seek to make good on their early promise
by Jeannie Wraight and David Miller
Over the past several years, momentum for the...
BIT225: HIV VPU Inhibitor Candidate
Contender in the Ring
A novel HIV therapy targets & eradicates one cell type in the viral reservoir
by Jeannie Wraight
BIT225, an HIV VPU inhibitor, has...
Targeting HIV Reservoirs
Hiding Place
One focus of the amfAR 2016 CURE Summit targeted HIV reservoirs
by Jeannie Wraight
This year, amfAR marked World AIDS Day with the 2016 HIV...
Orphaned Vaccines
Sometimes viewing a complex issue in its most simplistic form can help us to understand where a problem lies. HIV is a virus that...
Expediting Research
GlaxoSmithKline (GSK) and the University of North Carolina at Chapel-Hill (UNC) will launch a jointly owned novel HIV Cure Center, as well as a...
Eye on the Future
Towards an HIV Cure is an initiative of the International AIDS Society (IAS) formed to help direct and facilitate discussion, research and policy to...